Literature DB >> 15800009

A comparison of two primary care trials on tennis elbow: issues of external validity.

N Smidt1, M Lewis, E M Hay, D A W M Van der Windt, L M Bouter, P Croft.   

Abstract

OBJECTIVE: To assess clinical heterogeneity across two studies with respect to study population, interventions, and outcome measures, and to evaluate the influence of these sources of heterogeneity on the results of the studies.
METHODS: The individual patient data were used from two randomised controlled trials investigating the effectiveness of conservative treatments in patients with tennis elbow in primary care. Patients were allocated at random to treatment with steroid injection, wait and see policy, non-steroidal anti-inflammatory drugs, placebo tablets, or physiotherapy. Outcome measures included severity of the main complaint, inconvenience of the elbow complaints, pain during the day, elbow disability, pain-free grip strength, and global improvement. All outcomes were assessed at 1, 6, and 12 months after randomisation.
RESULTS: The two study populations were similar with respect to age, sex, comorbid neck/shoulder complaints, and baseline scores for the severity of pain. However, significant differences were observed for employment status, duration of elbow complaints, dominant side affected, previous history of elbow complaints, and use of analgesics. Local injections differed between the two studies with respect to volume, number, and steroid preparation. However, after 1, 6, and 12 months, the treatment effects of steroid injections were very similar between the study populations.
CONCLUSIONS: Despite large differences in study population at baseline, the responses to steroid injections were remarkably similar. Also the responses to other conservative interventions and the placebo treatment were very consistent, suggesting a uniform course of a tennis elbow and a lack of influence of clinical heterogeneity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15800009      PMCID: PMC1755250          DOI: 10.1136/ard.2004.029363

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

Review 1.  Tennis elbow (lateral epicondylitis).

Authors:  Willem Assendelft; Sally Green; Rachelle Buchbinder; Peter Struijs; Nynke Smidt
Journal:  Clin Evid       Date:  2002-12

2.  Prevalence, incidence, and remission rates of some common rheumatic diseases or syndromes.

Authors:  E Allander
Journal:  Scand J Rheumatol       Date:  1974       Impact factor: 3.641

3.  Corticosteroid injections, physiotherapy, or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial.

Authors:  Nynke Smidt; Daniëlle A W M van der Windt; Willem J J Assendelft; Walter L J M Devillé; Ingeborg B C Korthals-de Bos; Lex M Bouter
Journal:  Lancet       Date:  2002-02-23       Impact factor: 79.321

4.  Pragmatic randomised controlled trial of local corticosteroid injection and naproxen for treatment of lateral epicondylitis of elbow in primary care.

Authors:  E M Hay; S M Paterson; M Lewis; G Hosie; P Croft
Journal:  BMJ       Date:  1999-10-09

5.  The etiology and conservative treatment of humeral epicondylitis.

Authors:  P Kivi
Journal:  Scand J Rehabil Med       Date:  1983

6.  The prevalence of humeral epicondylitis: a survey in general practice.

Authors:  P G Hamilton
Journal:  J R Coll Gen Pract       Date:  1986-10
  6 in total
  2 in total

1.  Mobilisation with movement and exercise, corticosteroid injection, or wait and see for tennis elbow: randomised trial.

Authors:  Leanne Bisset; Elaine Beller; Gwendolen Jull; Peter Brooks; Ross Darnell; Bill Vicenzino
Journal:  BMJ       Date:  2006-09-29

2.  Low-level laser therapy (LLLT; 780 nm) acts differently on mRNA expression of anti- and pro-inflammatory mediators in an experimental model of collagenase-induced tendinitis in rat.

Authors:  Débora Pires; Murilo Xavier; Tiago Araújo; José Antônio Silva; Flavio Aimbire; Regiane Albertini
Journal:  Lasers Med Sci       Date:  2010-08-25       Impact factor: 3.161

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.